What FDA CRLs Reveal
White Paper Series
Since the FDA began publishing Complete Response Letters (CRLs), we’ve been analyzing them to uncover where drug applications fall short and how to avoid the same pitfalls. The result is a growing library of white papers translating real regulatory feedback into actionable insights.
So far, we have launched three white papers, each addressing critical areas of regulatory scrutiny: Extractables and Leachables (E&L), Container Closure Integrity Testing (CCIT), and Method Validation.
Fill out the form below to unlock the series and access practical recommendations grounded in real FDA feedback.

What you will learn
FDA CRL Insights
Discover the most common deficiencies cited in recent FDA Complete Response Letters
Proactive Strategies
Learn practical strategies to avoid the same mistakes and strengthen regulatory submissions
Specific Insights
Learn how E&L, CCIT, and method validation issues are interpreted by regulators
